{"id":9286,"date":"2024-05-10T16:05:00","date_gmt":"2024-05-10T08:05:00","guid":{"rendered":"https:\/\/www.excelsiormedical.com.tw\/?p=9286"},"modified":"2024-05-11T10:20:08","modified_gmt":"2024-05-11T02:20:08","slug":"the-board-of-directors-approved-q1-2024-consolidated-financial-statements","status":"publish","type":"post","link":"https:\/\/www.excelsiormedical.com.tw\/en\/investors\/the-board-of-directors-approved-q1-2024-consolidated-financial-statements\/","title":{"rendered":"The Board of Directors approved Q1 2024 consolidated financial statements."},"content":{"rendered":"<p>&nbsp;<\/p>\n<table class=\"hasBorder\">\n<tbody>\n<tr>\n<td class=\"tblHead\">SEQ_NO<\/td>\n<td class=\"odd\">\u00a01<\/td>\n<td class=\"tblHead\">Date of announcement<\/td>\n<td class=\"odd\">2024\/05\/10<\/td>\n<td class=\"tblHead\">Time of announcement<\/td>\n<td class=\"odd\">16:05:34<\/td>\n<\/tr>\n<tr>\n<td class=\"tblHead\">Subject<\/td>\n<td class=\"odd\" colspan=\"5\">\n<pre>The Board of Directors approved Q1 2024 consolidated financial statements.<\/pre>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"tblHead\">Date of events<\/td>\n<td class=\"odd\">2024\/05\/10<\/td>\n<td class=\"tblHead\">To which item it meets<\/td>\n<td class=\"odd\" colspan=\"3\">paragraph\u00a031<\/td>\n<\/tr>\n<tr>\n<td class=\"tblHead\">Statement<\/td>\n<td class=\"odd\" colspan=\"5\">\n<pre>1.Date of submission to the board of directors or \r\n  approval by the board of directors:2024\/05\/10\r\n2.Date of approval by the audit committee:2024\/05\/10\r\n3.Start and end dates of financial reports or annual\r\n  self-assessed financial information of the \r\n  reporting period (XXXX\/XX\/XX~XXXX\/XX\/XX):\r\n  2024\/01\/01~2024\/03\/31\r\n4.Operating revenue accumulated from 1\/1 to end of \r\n  the period (thousand NTD):2,042,037\r\n5.Gross profit (loss) from operations accumulated \r\n  from 1\/1 to end of the period (thousand NTD):411,941\r\n6.Net operating income (loss) accumulated from 1\/1 to \r\n  end of the period (thousand NTD):165,517\r\n7.Profit (loss) before tax accumulated from 1\/1 to \r\n  end of the period (thousand NTD):273,935\r\n8.Profit (loss) accumulated from 1\/1 to end of the\r\n  period (thousand NTD):226,472\r\n9.Profit (loss) during the period attributable to \r\n  owners of parent accumulated from 1\/1 to end of the\r\n  period (thousand NTD):185,177\r\n10.Basic earnings (loss) per share accumulated from \r\n   1\/1 to end of the period (NTD):1.19\r\n11.Total assets end of the period (thousand NTD):\r\n   18,414,696\r\n12.Total liabilities end of the period (thousand NTD):\r\n   7,941,640\r\n13.Equity attributable to owners of parent end of the\r\n   period (thousand NTD):8,348,429\r\n14.Any other matters that need to be specified:None.\r\n<\/pre>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; SEQ_NO \u00a01 Date of announcement 2024\/05\/10 Time of announcement 16:05:34 Subject The Board of Directors approved Q1 2024 consolidated financial statements. Date of events 2024\/05\/10 To which item it meets paragraph\u00a031 Statement 1.Date of submission to the board of directors or approval by the board of directors:2024\/05\/10 2.Date of approval by the audit committee:2024\/05\/10 &hellip;<\/p>\n<p class=\"read-more\"> <a class=\"\" href=\"https:\/\/www.excelsiormedical.com.tw\/en\/investors\/the-board-of-directors-approved-q1-2024-consolidated-financial-statements\/\"> <span class=\"screen-reader-text\">The Board of Directors approved Q1 2024 consolidated financial statements.<\/span> Read More &raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[102,72],"tags":[],"class_list":["post-9286","post","type-post","status-publish","format-standard","hentry","category-material-information","category-investors"],"_links":{"self":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9286","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/comments?post=9286"}],"version-history":[{"count":1,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9286\/revisions"}],"predecessor-version":[{"id":9287,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/posts\/9286\/revisions\/9287"}],"wp:attachment":[{"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/media?parent=9286"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/categories?post=9286"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.excelsiormedical.com.tw\/en\/wp-json\/wp\/v2\/tags?post=9286"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}